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Approximately 30-50% of the world's adult population suffer from arterial 
hypertension, and only 30-35% is successfully treated. A large number of patients with 
arterial hypertension require a combination of antihypertensive medications to achieve 
target blood pressure. The ESH/ESC recommendations suggest the use of fixed dose 
combinations for treatment simplification and improved adherence to treatment. 
The aim of this study was to evaluate efficacy and safety of fixed ramipril + 
felodipine combination in therapy of essential arterial hypertension.  
This multicentric, cross-sectional, non-interventional study evaluated 1.341 adult 
patients with essential arterial hypertension, defined by systolic and diastolic blood 
pressure increase (BP≥140/90 mmHg), only systolic blood pressure increase or 
antihypertensive therapy usage. All patients were treated with fixed-dose combination 
therapy ramipril + felodipine (5+5mg and 2.5+2.5mg) (Triapin® and Triapin mite®) 
therapy for at least two months. Efficacy was evaluated by proportion of patients who 
achieved target blood pressure values (<140/90 mmHg and <130/80 mmHg in 
diabetics) or defined blood pressure reduction (≥15/10mmHg). Safety of ramipril + 
felodipine therapy was evaluated based on the incidence of adverse events (AE) and 
therapy discontinuation rate during observational period. Therapy prescription was 
based on physician decision according to everyday clinical practice and 15 consecutive 
eligible patients were enrolled by each physician from the cohort of hypertensive 
patients treated in ambulatory setting. 
Patient population consisted of 647 (48.4%) males and 690 (51.7%) females (mean 
age 60.15±11.84 and mean duration of hypertension 9.5±7.34 years). Males were 
significantly younger (58.74±15.5 vs. 61.45±11.04, p<0.01) without difference in body 
mass index. There were 47.5% of patients with stage II, 29.2% with stage I and 23.3% 
with stage III. There was a significant reduction of systolic/diastolic BP and heart rate in 
patients with ramipril + felodipine combination (162.6±17/97.2±9 mmHg and 79.4±12/min) 
compared to baseline values prior to treatment (136.9±17/84.2±9 mmHg and 73.2±10 
/min, p<0.01). Group with Triapin mite had lower reduction of systolic/diastolic BP 
compared to Triapin 21.4±15.9/11.6±9.8 vs. 28.9±19.2/14.1±11.0 mmHg and lower 
reduction of heart rate 6.1 vs. 6.3 /min (p<0.01). In total, 39.3% of patients reached 
target BP with or without target BP reduction, 30.0% reached only BP reduction and 
30.7% did not reach target values. More patients reached target BP (48.4 vs 32.%) and 
less achieved defined BP reduction (18.8 vs. 38.9%) on Triapin mite therapy compared 
to Triapin (p<0.01). The proportion of patients who failed to reach any of these 
endpoints is similar in both treatment modalities. AEs were present in 34 patients 
(2.5%): headache in 9 (0.7%), lower leg swelling in 8 (0.6%) and dry cough in 4 
(0.2%) cases – these were reported as the most frequent. None of reported adverse 
events was serious. Therapy continuation was reported in 92.6% of patients. Reasons 
for therapy discontinuation were insufficient drug efficacy in 29 (2.2%) patients; AE in 
28 (2.1%) patients and other reasons in 34 (2.6%) patients. Triapin therapy efficacy 
and safety evaluated by physicians were: excellent efficacy in 824 (61.4%) patients and 
excellent safety in 870 (64.9%) patients. 
Fixed dose combination of ramipril + felodipine was shown to be an effective 
antihypertensive therapy in patients with essential arterial hypertension and an 
alternative approach to monotherapy for the initial management of essential 
hypertension. Small proportion of patients discontinued from ramipril+felodipine therapy 
and rare AEs indicate excellent safety profile. Acta Medica Medianae 2013;52(1): 16-24. 
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Introduction 
 
  Cardiovascular (CV) diseases are the leading 
cause of death in Europe (over four million 
people each year), this number represents about 
half (47%) of all deaths in Europe and 40% in 
the European Union. Cardiovascular diseases 
caused a total of 17.1 million people deaths in 
2004 worldwide, or 29% of all deaths in the 
world. Cardiovascular disease is the main cause 
of death in women in all countries of Europe and 
is the main cause of death in men in almost all 
EU countries (1). With proportion of 57.6%, they 
were also the leading cause of mortality in Serbia Acta Medica Medianae 2013, Vol.52(1)                                         Efficacy and safety of fixed Ramipril + Felodipine combination... 
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in 2006, with higher percentage of deaths in 
females - 53.9% (2). 
  CV mortality is now decreasing in most 
European countries, including Central and Eastern 
European countries which evidenced large increases 
until the beginning of the 21
st century (1). The 
largest percentage of increase is predicted in the 
eastern Mediterranean region, while the largest 
increase in the number of deaths is expected in 
the region of Southeast Asia (3). 
  Arterial hypertension is still the leading 
independent risk factor for CV morbidity and 
mortality. It has been estimated that more than 
25% of the world's adult population had hyper-
tension in year 2000 and that this figure is 
expected to increase by 60% to 1.56 billion by 
2025 (4). The risk of CV complications is 
proportional to increase in blood pressure in both 
sexes of all age groups. Also, as a CV risk factor, 
it does not act alone, because consequences of 
high blood pressure depend on association with 
other risk factors (age, sex, race, diabetes, 
presence of previous CV disease, smoking, high 
blood lipids, and family burden). According to the 
World Health Organization (WHO), approximately 
30-50% of the world's adult population suffer 
from hypertension, and only 30-35% of them are 
successfully treated and maintain their blood 
pressure under control (5). It is estimated that 
46.5% of adult population in Serbia are 
hypertensive (2). 
  Framingham Heart Study showed a marked 
benefit from the use of antihypertensive therapy 
over a longer period of time, with reduced total 
mortality by 31% and CV mortality by 60% (6). 
  The ESH/ESC 2009 recommendations confirm 
instructions from 2007, that is - diuretics, ACE 
inhibitors, calcium antagonists, angiotensin receptor 
antagonists, and beta-blockers are eligible for starting 
the antihypertensive treatment, and sub-sequent 
treatment (7). The ESH/ESC 2009 recommenda-
tions suggest that whenever possible a fixed dose 
(or one tablet) combinations should be used, as a 
treatment simplification improves adherence to 
treatment (8,9). Also, it appears that the vast 
majority of patients with arterial hypertension 
requires a combination (at least two drugs) of 
antihypertensive medications to achieve target 
blood pressure (7,8). The number of drugs (tablets) 
is one of the important factors (age, more drugs, 
drug taking in more daily doses, cost and safety 
of the drug) that act on compliance. Data show 
that only one third of patients have good 
adherence to antihypertensive therapy after six 
m o n t h s  o f  t h e r a p y .  I t  i s  w e l l  k n o w n  t h a t  f i x e d  
combinations of antihypertensive drugs improve 
therapy adherence up to 24-26% (10). 
  According to ESH/ESC guidelines, a fixed 
dose combination with calcium channel anta-
gonist (CCA) and angiotensin converting enzyme 
inhibitor (ACE) is one of the preferred combi-
nation in the treatment of arterial hypertension 
(7). 
 
  Aim  
 
  The aim of this study was to evaluate the 
efficacy and safety of fixed ramipril+felodipine 
combination in therapy of essential arterial 
hypertension.  
 
  Methodology 
 
  Study design:  
  Patients in this multicentric, cross-sectional, 
non-interventional study were recruited by 95 
physicians in 25 cities across Serbia. Study sites 
were selected according to a number of hyper-
tensive patients treated and their geographic 
distribution. According to clinical practice and 
study design, patients observation and data 
collection were done once during each patient’s 
visit to a physician in a cross sectional manner. 
The data were collected from patient’s records 
retrospectively and from clinical examination 
undertaken during the visit. Patients’ written 
informed consent was obtained prior to the 
conduct of any study-related procedure. 
 
 Patients: 
  Study enrolled 1.341 male and female 
patients aged ≥18 years, with moderate-to-severe 
essential hypertension defined by increased systolic 
and diastolic pressure (BP ≥140/90 mmHg),  only 
systolic blood pressure increase (isolated systolic 
hypertension) or antihypertensive therapy appli-
cation. Baseline characteristics of study patients 
are described in Table 1. 
  Patients were selected by physician according 
to inclusion/exclusion criteria. Each investigator 
included 15 consecutive hypertensive patients 
observed in ambulance setting treated with 
ramipril+felodipine combination for at least two 
months. 
 
 Treatment: 
    At the time of the visit all patients were 
treated with fixed-dose combination therapy 
ramipril+felodipine (Triapin® and Triapin mite®) 
for at least two months. The TRIAPIN mite (2.5 
mg+ 2.5 mg) therapy was prescribed in 580 
(44.1%) of patients, while 735 (55.9%) patients 
was using TRIAPIN (5 mg + 5 mg) therapy, Table 2.  
  Therapy was prescribed by physician 
according to everyday clinical practice and the 
assignment of the patient to a particular 
therapeutic strategy was not decided in advance 
by the trial protocol. 
 
 Measurements: 
  Primary outcome variable is efficacy of 
fixed dose combined therapy ramipril+ felodipine. 
Efficacy was estimated by proportion of patients 
achieving target blood pressure (<140/90 mmHg 
and <130/80 mmHg in diabetics) or defined 
blood pressure reduction (≥15/10mmHg) compared 
to baseline values prior to treatment with fixed-
dose combination. 
  Classification of blood pressure (BP) levels 
(mmHg) is done according to ESC recommen-
dations (Grade 1 hypertension 140–159 and/or 
90–99; Grade 2 hypertension 160–179 and/or Efficacy and safety of fixed Ramipril + Felodipine combination...                                                                          Ivan Tasić  et al. 
values, except lower heart rate in males (Table 
1). The dosage of fixed dose combination is shown 
in Table 2. 
100–109; Grade 3 hypertension ≥180 and/or 
≥110mmHg) (11). The BP measured before therapy 
initiation was used for BP classification.  
  Inadequate hypertension regulation during 
previous treatment was the most common reason 
for fixed combination of ramipril + felodipin 
initiation, in 1.144 (85.3%) patients; compliance 
improvement in good regulated hypertension, in 
348 (26.0%) patients and other reasons in 43 
(3.2%) patients. 
  Safety of ramipril+felodipine therapy was 
estimated by incidence of adverse events (AE) / 
adverse drug reaction (ADR) and therapy 
discontinuation during the observational period. 
 
  Date and place: 
  Study was conducted during the period 
from September 2010 to October 2011.     About half of patients have stage II hyper-
tension, while approximately one quarter of 
patients have stage I and another quarter stage 
III (Graph 1). 
 
  Data collection and statistical analyses: 
  Data was collected on paper case report 
form (CRF) during regular medical visit and then 
entered into electronic database. All case report 
forms were monitored for completeness and 
accuracy. Baseline data included demographics, 
medical history, risk factors, physical examination, 
cardiac parameters. Other collected data included 
treatments of hypertension, adverse events and 
efficacy data. 
  Efficacy of therapy is measured by reduction 
of blood pressure, heart rate reduction and 
achieved target BP values (Graphs 2-4). 
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  Statistical analyses were performed for all 
patients who completed the study. Continuous 
data are presented as mean values with standard 
deviations or as medians with interquartile 
ranges (for skewed data). Categorical data are 
presented by absolute numbers with percentages. 
Comparisons of mean changes in SBP/DBP and 
heart rate between starting and final treatment 
values were performed using a paired t-test. 
Other parametric examination were done by 
independent samples t test. 
    
  Results  Graph 1. Distribution of patients according to 
hypertension stages determined by starting BP    
    Males enrolled in the study were younger 
and with shorter duration of hypertension compared 
to females (p<0.05). There were no significant 
differences in cardiovascular parameters and BMI  
Stage I (systolic BP 140-159 / diastolic BP 90-99 mmHg);  
Stage II (systolic BP 160-179 / diastolic BP 100-109 mmHg);  
Stage III (systolic BP >180 / diastolic BP >110 mmHg) 
 
 
Table 1. Baseline characteristics of study patients 
 
 Males  Females  Total 
Number / %  647 / 48.4  690 / 51.6  1337 / 100.0 
Age (years)  58.74±15.5*  61.45±11.04  60.15±11.8 
BMI (kg/m2)  28.3±3.7  28.0±4.3  28.1±4.0 
Duration of hypertension (years)  8.9±7.0*  10.0±7.5  9.5±7.3 
Waist circumference (cm)  100.02±11.3*  91.2±13.2  95.4±13.2 
Systolic BP (mmHg)  161.9±16.9  163±18.6  162.7±17.8 
Diastolic BP (mmHg)  97.6±9.7  93.8±9.5  97.2±9.6 
Heart rate (/min)  78.3±12.2*  80.2±12.3  79.4±12.3 
  Data are presented as mean±SD; *p<0.05 
 
Table 2. Fixed dose combination therapy (ramipril + felodipine) of hypertension: TRIAPIN mite and TRIPIN therapy 
 
 Therapy  Frequency  Percent  Valid  Percent 
TRIAPIN mite  580  43.3  44.1 
TRIAPIN 735  54.8 55.9 
Missing 26  1.9   
Valid 
Total 1341  100.0   
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Graph 2. Therapy efficacy measured by systolic/diastolic BP reduction 
Heart rate
73.29 79.43**
0
10
20
30
40
50
60
70
80
90
100
before after
/min
 
      **p<0.01 
Graph 3. Therapy efficacy measured by heart rate reduction 
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Graph 4. Therapy efficacy measured by achievement of target BP values and/or defined BP reduction. 
  I - (reached target BP <140/90mmHg in general and <130/80 mmHg in diabetics) with or without reaching  
  defined BP reduction ≥15/10 mmHg;  
  II - reached only defined BP reduction ≥15/10 mmHg;  
  III-not reached target BP nor defined BP reduction  
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Table 3. Therapy efficacy attributed to therapy dose 
 
   ramipril + felodipine 
2.5/2.5 mg 
ramipril + felodipine 
5/5 mg 
Age (years)  59.5±12.7*  60.8±11.0 
BMI (kg/m2)  27.2±3.7*  28.8±4.1 
Waist circumference (cm)  92.7±13.1*  97.8±12.6 
Duration of hypertension (years)  8.09±6.8*  10.6±7.5 
Systolic BP (mmHg)  133.3±14.9*  139.7±18.0 
Diastolic BP (mmHg)  82.4±8.9*  85.6±9.9 
Heart rate (/min)  72.3±10.0*  74.0±10.1 
Previous systolic BP (mmHg)  154.8±13.2*  168.9±18.5 
Previous diastolic BP (mmHg)  94.0±8.2*  99.8±9.9 
Previous heart rate ( /min)  78.6±11.9*  80.1±12.6 
Average reduction systolic BP (mmHg)  21.4±15.9*  28.9±19.2 
Average reduction diastolic BP (mmHg)  11.6±9.8*  14.1±11.0 
     *p<0.05 vs. ramipril+felodipine 5/5mg 
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       *p<0.05 vs. Triapin 
Graph 5. Therapy efficacy according to dose of ramipril+felodipin fixed combination 
  I- (reached target BP <140/90mmHg in general and <130/80 mmHg in diabetics) with or without reaching  
       defined BP reduction ≥15/10 mmHg;  
  II - reached only defined BP reduction ≥15/10 mmHg;  
  III-not reached target BP nor defined BP reduction  
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Graph 6. Therapy adverse events 
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Graph 7. Other reasons for ramipril+felodipin discontinuation in total of 34 patients 
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 Graph 8. Ramipril+felodipin therapy efficacy assessed 
by physicians 
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Graph 9. Ramipril+felodipin therapy safety assessed by 
physicians 
  Baseline values (systolic and diastolic blood 
pressure as well as heart rate) were significantly 
reduced after at least two months of therapy with 
ramipril+felodipine fixed dose combination (p<0.01) 
(Graphs 2,3). 
  The analysis showed that 39.3% of patients 
from the total number of 1.341 subjects reached 
the target BP; 30.01% of patients reached 
defined BP reduction without reaching target BP 
and 30.7% of patients did not reach the target 
BP nor defined reduction of BP (Graph 4). 
  Patients with lower dose of ramipril+felodipin 
combination were younger, less obese, with better 
cardiovascular parameters and shorter duration of 
hypertension. The lower dose ramipril+ felodipin 
combination also showed a lower average 
reduction of systolic/diastolic blood pressure 
(p<0.05) when compared to a higher dose of 
ramipril+felodipine 5/5mg (Table 3). 
  The proportion of patients reaching the 
target BP values or target BP reduction is shown 
in Graph 5. Patients with lower dose of ramipril+ 
felodipin therapy combination more often reached 
the target BP values, but less often reached 
defined BP reduction ≥15/10mmHg (p<0.05) 
(Graph 5). 
  Therapy continuation: The ramipril + felo-
dipine therapy continuation was reported for 
1.242 (92.6%) patients and discontinuation in 99 
(7.4%). The main reasons for ramipril+feldopin 
discontinuation were: insufficient efficacy 29 
(2.2%), adverse events 28 (2.1%) and other 
reasons 34 (2.6%). Adverse events are presented 
in Graph 6. 
  Adverse events were reported by 34 
patients. Nine patients reported headache (0.7%) 
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and eight patients reported the lower leg swelling 
(0.6%) as the most frequent adverse events. 
None of reported adverse events were serious 
(Graph 6). 
    Ramipril+felodipine therapy efficacy and 
safety are shown in Graphs 8 and 9. Excellent 
efficacy was reported in 824 (61.4%) patients 
and excellent safety was reported in 870 (64.9%) 
patients. 
 
  Discussion 
 
  Hypertension is a leading modifiable risk 
factor for cardiovascular disease. There is a direct 
relationship between blood pressure and risk of 
cardiovascular disease. It is shown that reduction 
of diastolic blood pressure by 2mm Hg reduces 
the risk of coronary artery disease by 6% and 
CVD/TIA by 15% (12). Treatment of patients 
with arterial hypertension varies within a wide 
range, but it can be generally stated that it is far 
from the optimal target level. During the period 
between 2005 and 2008, the overall age-
adjusted prevalence of hypertension control 
among adult hypertension patients was 43.7% 
(13). 
  Triapin mite (2.5 mg + 2.5 mg) and Triapin 
(5 mg + 5 mg) are indicated in patients with 
blood pressure that cannot be adequately 
controlled using only felodipine or ramipril. Both 
components of the drug, calcium antagonist 
felodipine and angiotensin converting enzyme 
inhibitor (ACE) ramipril lower blood pressure 
causing the dilatation of peripheral blood vessels. 
Calcium antagonists dilate arterial blood vessels, 
while ACE inhibitors dilate both arterial and 
venous blood vessels. Vasodilatation and conse-
quent reductions in blood pressure can lead to 
the activation of the sympathetic nervous system 
and the renin-angiotensin system. Inhibition of 
ACE results in a decrease in angiotensin II 
plasma concentrations (14). 
 The  felodipine+ramipril  fixed  combination 
therapy was shown to be more effective than 
monotherapy with these drugs, even when drugs 
were administered at higher doses (10 mg) (15-
18). Starting values of study patient’s blood 
pressure and heart rate were significantly 
reduced after at least two months of therapy. 
This corresponds to the results of other studies 
where treatment with the fixed dose combination 
was significantly more effective in reducing 
systolic and diastolic BP (-15.8/-9.2 mmHg) 
compared to its monocomponents, ramipril (-
7.6/-3.8 mmHg) and felodipine ER (-8.0/-5.0 
mmHg) (15,19). It is of interest that reduction 
observed in the FORECAST study is twice higher. 
  Patients with higher grade of hypertension 
are usually with higher therapeutic dose and, as 
expected, they more often reached the target BP 
reduction, but les often the target BP value. On 
the other hand, patients with lower BP grade 
usually used a mite drug formulation and they 
often reached the target values but not the 
target BP reduction. This result is not only the 
consequence of the starting BP grade but also it 
arises from the fact that patients with lower dose 
ramipril+felodipin combination were younger, 
less obese, with better cardiovascular parameters 
and shorter duration of hypertension.  
  Ramipril+felodipin therapy was discontinued 
in 7.4% of patients due to insufficient product 
efficacy in 2.2%, adverse events in 2.1% and 
other reasons in 2.5% of patients. Slightly lower 
percentage (5.1%) of discontinuation was reported 
in Poisson et al. study (16) because of adverse 
events, but without clear pattern in regard to 
specific events leading to withdrawal. Bainbridge 
et al. (18) observed that felodipin attributable 
headache was not attenuated by co-admini-
stration of ramipril. Similar findings indicate that 
reported adverse events were mild, and smaller 
number of patients treated with fixed-dose 
combination reported adverse events (19). 
Similar study evaluating safety and tolerability of 
combination therapy showed there were fewer 
cases of peripheral edema with a combination 
therapy than with felodipine monotherapy. About 
5.1% of patients withdrew from the study 
because of adverse events, but there was no 
clear pattern with regard to the specific events 
leading to withdrawal. All this is in line with the 
results obtained in FORECAST study (16). 
 
  Conclusion 
 
  The fixed dose combination of ramipril+ 
felodipine (Triapin® and Triapin Mite®) was shown 
to be an effective antihypertensive therapy in 
patients with essential arterial hypertension and an 
alternative approach to monotherapy for the 
initial management of essential hypertension. 
Ramipril+felodipine appear to be an effective 
option for the treatment of adults with essential 
hypertension that is poorly controlled with 
monotherapy. 
  Small proportion of patients discontinued 
ramipril+felodipine therapy and rare AE indicate 
excellent safety profile. In clinical setting, this 
therapy showed excellent compliance, efficacy 
and safety indicated by patients and physicians. 
  Great incidence of comorbidities, mainly 
heart disease and presence of cardiovascular risk 
factors, indicate the pathogenetic role of essential 
hypertension in target organs damage. The great 
cardiovascular risk factors load is one of the 
possible explanations for relatively great proportion 
of patients with uncontrolled hypertension and 
indicates the need for multidrug therapeutic 
approach in therapy of essential hypertension. 
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Oko 30-50% ukupne svetske odrasle poplulacije boluje od arterijske hipertenzije, a 
samo 30-35% su uspešno lečeni. Veliki broj bolesnika sa arterijskom hipertenzijom 
zahteva kombinaciju antihipertenzivnih lekova da bi dostigli željeni krvni pritisak. 
Prema preporukama ESH/ESC koristi se fiksna doza kombinacije za pojednostavljenu i 
poboljšanu terapiju. 
Cilj ove studije bio je da se proceni efikasnost i bezbednost fiksne kombinacije 
lekova ramipril + felodipin u terapiji esencijalne arterijske hipertenzije.  
Ova multicentrična, ukrštena, neintervencionalna studija  obuhvatila je 1341 
odraslog bolesnika sa esencijalnom arterijskom hipertenzijom, definisanom kao porast 
sistolnog i dijastolnog krvnog pritiska (≥ 140/90 mmHg), porast samo sistolnog krvnog 
pritiska ili korišćenje antihipertenzivne terapije. Svi bolesnici su tretirani fiksnom 
dozom lekova kombinovane terapije ramipril + felodipin (5+5mg and 2.5+2.5mg) 
(Triapin® i Triapin mite®) najmanje dva meseca. Efikasnost je procenjivana 
procentom bolesnika koji su dostigli adekvatan krvni pritisak (<140/90 mmHg i 
<130/80 mmHg in diabetics) ili definisano smanjenje krvnog pritiska (≥15/10mmHg). 
Procena bezbednosti terapije ramiprilom + felodipinom zasnivala se na incidenci 
neželjenih efekata i  stopi prekida terapije u toku perioda posmatranja. Propisivanje 
terapije zasnivalo se na odluci kliničara na osnovu svakodnevnog iskustva iz kliničke 
prakse i 15 bolesnika koje je izabrao i uključio svaki kliničar među mnoštvom bolesnika 
sa hipertenzijom koji su lečeni u ambulanti.  
Grupu bolesnika činilo je 647 (48.4%) muškaraca i 690 (51.7%)  žena (prosečna 
starost 60.15±11.84 i prosečna dužina trajanja hipertenzije 9.5±7.34 godina). 
Muškarci su bili značajno mlađi (58.74±15.5 prema 61.45±11.04, p<0.01)  bez razlike 
u indeksu telesne mase. U drugom stadijumu bilo je 47.5% bolesnika, 29.2% u prvom 
i 23.3% u trećem. Uočeno je značajno smanjenje sistolnog/dijastolnog krvnog pritiska i 
pulsa kod bolesnika sa ramipril + felodipin kombinacijom  (162.6±17/97.2±9 mmHg i 
79.4±12/min) u poređenju sa vrednostima  pre tretmana (136.9±17/84.2±9 mmHg i 
73.2±10 /min, p<0.01). Grupa sa lekom Triapinom mite imala je manju redukciju 
sistolnog/dijastolnog krvnog pritiska u poređenju sa Triapinom 21.4±15.9/11.6±9.8 
prema 28.9±19.2/14.1±11.0 mmHg i manju redukciju pulsa 6.1 prema 6.3 /min 
(p<0.01). Ukupno 39.3% bolesnika dostiglo je odgovarajući krvni pritisak, 30.0% 
dostiglo je samo definisanu redukciju krvnog pritiska, dok 30.7% nije dostiglo 
odgovarajuće vrednosti. Veći broj bolesnika dostigao je odgovarajući krvni pritisak 
(48.4 prema 32.%), a manji broj je dostigao definisano smanjenje krvnog pritiska 
(18.8 prema 38.9%) kod terapije Triapinom mite u poređenju sa terapijom Triapinom 
(p<0.01). Procenat bolesnika koji nisu dostigli ni jednu od graničnih vrednosti sličan je 
kod oba modaliteta terapije. Neželjeni efekti bili su prisutni kod 34 bolesnika (2.5%): 
glavobolja 9 (0.7%), znojenje donjih ekstremiteta 8 (0.6%) i suv kašalj 4 (0.2%) bili 
su najčešće prijavljivani. Ni jedan od prijavljenih neželjenih efekata  nije bio ozbiljan. 
Nastavak terapije bio je prijavljen kod 92.6% bolesnika. Razlozi za prekidanje terapije 
bili su nedovoljna efikasnost leka kod 29 (2.2%); neželjeni efekti 28 (2.1%) i ostali 
razlozi 34 (2.6%). Procenjena efikasnost i bezbednost terapije Triapinom: odlična 
efikasnost kod 824 (61.4%) i odlična bezbednost kod 870 (64.9%) bolesnika. 
Pokazano je da je kombinacija fiksnih doza lekova ramipril + felodipin efikasna 
antihipertenzivna terapija kod bolesnika sa esencijalnom arterijskom hipertenzijom i 
alternativa monoterapiji za početno regulisanje arterijske hipertenzije. Ukinuta terapija 
ramipril+felodipin i retka pojava neželjenih efekata malom broju bolesnika označavaju 
odličan bezbednosni profil leka. Acta Medica Medianae 2013;52(1):16-24. 
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